MAULDIN, SC – Xcelerate Inc. (OTC: XCRT) today announced that its majority-owned subsidiary, AfiyaSasa Africa LLLC, is currently in discussions with several medical consultants and healthcare experts to support the next phase of the Company’s AfiyaSasa Africa initiative. These discussions represent an operational step toward implementing the strategic direction outlined in the Company’s recent year-end update, which highlighted plans to explore artificial intelligence-enabled healthcare delivery models in underserved markets.
The next phase of work for AfiyaSasa Africa is expected to include reviewing the capabilities of the AdviNOW Medical system, identifying localization requirements, and compiling relevant clinical data aligned with regional treatment guidelines and pharmaceutical standards. In addition, the Company is evaluating potential consultants who may assist in identifying and assessing suitable clinical locations that could support a future pilot clinic program intended to demonstrate a proof-of-concept deployment. Xcelerate expects that formal consulting agreements will be finalized as these discussions progress and the scope of work for the next phase of the initiative is defined. The Company anticipates announcing finalized consulting agreements related to the next phase of the AfiyaSasa Africa initiative during the current quarter.
Michael O’Shea, Chief Executive Officer of Xcelerate, commented: “In our recent strategic update, we noted that a key focus for 2026 would be moving from planning toward execution for the AfiyaSasa Africa initiative. We are currently engaging with several healthcare professionals and consultants to help evaluate how advanced healthcare technologies such as AdviNOW could be adapted for use in African healthcare environments. These discussions represent an important step as we work toward defining localization requirements and preparing for a potential pilot clinic Management believes the completion of this evaluation phase will provide important insight into the feasibility, cost structure, and operational framework required for introducing AI-supported healthcare systems in emerging markets.”
ABOUT XCELERATE INC.
In May 2020, Xcelerate commenced implementation of a new business plan that encompasses two separate but related businesses within the medical industry, including (i) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses and (ii) development of virtual health technology to assist patients in developing countries obtain medical care by extending the reach of physicians through the use of that technology.
For more information:
visit www.xcelerate.global;
or contact us at 854-900-2020
email info@xcelerate.global.
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forwardlooking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.